// App-Quantinova.ai

9510 : Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.

Researchers

Presenter

  • Jonathan S. Zager

Principal Investigators

  • Marlana Orloff

  • Pier Francesco Ferrucci

  • Evan Scott Glazer

  • Aslam Ejaz

  • Erika Richtig

  • Sebastian Ochsenreither

  • Michael C. Lowe

  • Sunil A. Reddy

  • Georgia Beasley

  • Anja Gesierich

  • Reinhard Dummer

  • Ana Maria Arance

  • Stephen William Fenwick

  • Matthew Wheater

  • Christian Ottensmeier

Medical Centers

  • H. Lee Moffitt Cancer Ctr, Tampa, FL, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, European Institute of Oncology–IRCCS, Milan, Italy

  • University of Tennessee Health Science Center, Memphis, TN, Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, OH, Medical University of Graz, Graz, Austria

  • Department of Hematology, Oncology and Tumor Immunology, Charite University Medicine, Campus Benjamin Franklin, Berlin, Germany

  • Emory University School of Medicine, Atlanta, GA, Stanford Cancer Institute, Stanford, CA

  • Duke University, Durham, NC, University Hospital Wuerzburg, Würzburg, Germany

  • Skin Cancer Center, University Hospital of Zürich, Zürich, Switzerland

  • Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain

  • Rheumatology, Liverpool University Hospitals Foundation Trust, Liverpool, United Kingdom

  • University of Southampton, Southampten, United Kingdom

  • Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, United Kingdom

Locations

  • Italy

  • Austria

  • Germany

  • Switzerland

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Secondary liver cancer

  • Ocular melanoma

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • dacarbazine Intravenous

  • Ipilimumab

  • Melphalan

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02678572

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved